Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
Immunexpress.com

Immunexpress Presents Data on Clinical Validation of SeptiCyte® RAPID for Diagnosing Sepsis at e-ISICEM

Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the presentation of analytical and clinical performance data for SeptiCyte® technology in two posters at the virtual e-ISICEM (International Symposium on Intensive Care and Emergency Medicine), from Sept. 15-18, 2020. The first poster, titled "Clinical...
Immunexpress.com

COVID-19: What’s Next?

During this COVID-19 pandemic, ICU doctors have frequently recognized that what they are observing in their severe COVID-19 patients, is in fact sepsis, defined as a life-threatening organ failure caused by a dysregulated immune response caused by infection. As a consequence Immunexpress was awarded a government...
360DX

Immunexpress, Biocartis to Roll Out Sepsis Test in Europe Ahead of Planned US Launch

Immunexpress and its partner Biocartis plan to introduce a new, rapid test for sepsis in Europe this quarter ahead of a potential US Food and Drug Administration 510(k) clearance for the assay later this year. The companies are positioning the test, called SeptiCyte Rapid, to triage COVID-19 patients who could...
SA_logo-V_CMYK

The Sepsis Alliance Summit

This September, Sepsis Alliance is proudly hosting the inaugural Sepsis Alliance Summit. Set to coincide with Sepsis Awareness Month and the annual Sepsis Heroes gala, the event will feature two days of learning and inspiration for healthcare providers, managers, policymakers, and industry leaders. Designed to explore an array of sepsis-related topics...
SA_logo-V_CMYK

9th Annual Sepsis Heroes Gala

Meet the 2020 Class of Sepsis Heroes From a grandfather, sepsis survivor, and advocate in North Carolina to a community hospital reducing sepsis mortality in Los Angeles, CA, this year’s Sepsis Heroes are making great strides in raising sepsis awareness and helping save lives in their communities and across the nation.  The 2020 Sepsis Heroes are:   Emanuel Rivers, MD, MPH, Vice Chairman and Director of Research in...
BMC Medicine_Blue 01_RGB

Blood transcriptomic discrimination of bacterial and viral infections in the emergency department: a multi-cohort observational validation study

Abstract Background There is an urgent need to develop biomarkers that stratify risk of bacterial infection in order to support antimicrobial stewardship in emergency hospital admissions. Methods We used computational machine learning to derive a rule-out blood transcriptomic signature of bacterial infection (SeptiCyte™ TRIAGE) from eight published case-control studies. We...
HPR logo 2

Immunexpress – Near-Patient Diagnostic For Sepsis – SeptiCyte® RAPID

Dr. Rollie Carlson, CEO of Immunexpress discusses the development and commercialization plans for SeptiCyte® RAPID.  SeptiCyte® RAPID is a test that quantifies the immune response to infection and will provide actionable results in about one hour to guide physicians when making patient management decisions.
Immunexpress.com

Immunexpress Awarded BARDA Contract to Develop SeptiCyte® RAPID for COVID-19 Patient Triage

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, has been awarded a grant from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS),...
applied-clinical-trials

Conquering Sepsis Clinical Trial Design

Designing and operating clinical trials for diagnosing sepsis can be a challenge, as the gold standard for sepsis detection offers a very low prediction rate due to the nature of how sepsis evolves in patients. FDA gold-standard septic blood cultures predict sepsis only 14% of the time, which makes it...
Express Healthcare

Biocartis Group partners with Immunexpress

For co-commercialisation agreement for SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla Biocartis Group recently announced the expansion of its partnership with Immunexpress with a co-commercialisation agreement for the SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla. The SeptiCyte RAPID...
genome web

Biocartis, Immunexpress Ink Co-Commercialization Agreement for Sepsis Test

Biocartis has expanded its current partnership with Seattle-based Immunexpress by launching a co-commercialization agreement for Immunexpress' SeptiCyte Rapid test on Biocartis' Idylla platform. As part of the expanded collaboration, Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the...
Immunexpress.com

Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID

Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership in Europe   SEATTLE and BRISBANE,...

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com